Advances in Bioengineering and Biomedical Science Research(ABBSR)
ISSN: 2640-4133 | DOI: 10.33140/ABBSR
Impact Factor: 1.7
Ofodire Emeka
Department of Pharmacology and Therapeutics, College of Medicine, University of, Nigeria
Publications
-
Research Article
Radium-223 Dichloride Related Toxicity in Post-Chemotherapy Castrate Resistant Prostate Cancer Patients Treated for Bone Metastases
Author(s): Ofodire Emeka
Background: Radiation pharmacokinetics and pharmacodynamics of Radium point to bone as its site of primary uptake and action. It is therefore very important to investigate the hematological and other toxicity of the radiopharmaceutical Radium -223 dichloride in the wake of its introduction for treatment of bone metastases. Methods: Five Patients with post-chemotherapy castrate resistant prostate cancer with bone metastases received 50kBq/ kg body weight of Radium-223 Dichloride injection every 4 weeks for 5 cycles. 1. Screening 2. Treatment (including an End of Treatment Visit) 3. Follow-up Results: The ranges of measured parameters for 4 patients at the end of 5th cycle (20th week) were within normal limits: Hb : Wk 20 = 110 -126g/l, pre-treatment = 110-136g/l (normal range 120-170) Wbc: Wk 20 = 3.3-6.2x109/l, Pre-treatment=3.5-8.9x109/l (normal range 4.5-10) Plat.. Read More»